Difference between revisions of "Varicella"

(VZIG)
(16 intermediate revisions by 7 users not shown)
Line 6: Line 6:
 
[[File:Varicela Rash.jpg|thumbnail|Male with varicella rash: lesions in various stages of development]]
 
[[File:Varicela Rash.jpg|thumbnail|Male with varicella rash: lesions in various stages of development]]
 
[[File:Chickenpox blister.jpg|thumbnail|Classic blister during early stage of lesion development]]
 
[[File:Chickenpox blister.jpg|thumbnail|Classic blister during early stage of lesion development]]
*Pruritic generalized vesicular exanthem w/ mild systemic manifestations
+
*Pruritic generalized vesicular exanthem with mild systemic manifestations
 
*Usually affects children <10y
 
*Usually affects children <10y
*Rash
+
 
**Starts on trunk or scalp as pruritic, red macules, spreads to extremities
+
===Rash===
**W/in 24hr rash becomes vesicular (on erythematous base)
+
*Starts on trunk or scalp as pruritic, red macules, spreads to extremities
**Palms/soles spared
+
*Within 24hr rash becomes vesicular (on erythematous base)
**Lesions in various stages of development
+
*Palms/soles spared
 +
*Lesions in various stages of development
  
 
==Differential Diagnosis==
 
==Differential Diagnosis==
 
{{Peds Rash DDX}}
 
{{Peds Rash DDX}}
 +
{{Bullous rashes DDX}}
 +
{{VZV types}}
  
{{VZV types}}
+
==Evaluation==
 +
*Typically made on clinical features
  
==Treatment==
+
==Management==
 
===Supportive Care===
 
===Supportive Care===
*Tylenol, antihistamine, oatmeal baths
+
*[[Tylenol]], [[antihistamine]], oatmeal baths
 
*Avoid aspirin in young children due to the risk of [[Reye syndrome]]
 
*Avoid aspirin in young children due to the risk of [[Reye syndrome]]
  
Line 33: Line 37:
 
*Patients receiving short, intermittent, or aerosolized courses of corticosteroids
 
*Patients receiving short, intermittent, or aerosolized courses of corticosteroids
  
Other cases to consider acyclovir
+
Other cases to consider [[acyclovir]]
*Also onsider in <ref>Drugs for non-HIV viral infections. Treat Guidel Med Lett. 2007; 5(59):59-70.</ref>:
+
*Also consider in <ref>Drugs for non-HIV viral infections. Treat Guidel Med Lett. 2007; 5(59):59-70.</ref>:
 
*Pregnancy<ref name="cdc">CDC Chicken pox acyclovir treatment [http://www.cdc.gov/chickenpox/hcp/persons-risk.html#acyclovir]</ref>
 
*Pregnancy<ref name="cdc">CDC Chicken pox acyclovir treatment [http://www.cdc.gov/chickenpox/hcp/persons-risk.html#acyclovir]</ref>
 
====Immunocompetent Adult====
 
====Immunocompetent Adult====
*Acyclovir 800mg PO q6hrs daily x 5 days OR
+
*[[Acyclovir]] 800mg PO q6hrs daily x 5 days '''OR'''
*Valacyclovir 1000mg PO q8hrs daily x 14 days OR
+
*[[Valacyclovir]] 1000mg PO q8hrs daily x 14 days '''OR'''
* Famiciclovir 500mg PO q8hrs x 14 days
+
*[[Famiciclovir]] 500mg PO q8hrs x 14 days
 
====Immunocompromised Adult====
 
====Immunocompromised Adult====
*Acyclovir 10mg/kg IV q8hrs x 7 days
+
*[[Acyclovir]] 10mg/kg IV q8hrs x 7 days
 
====At risk children <12yo child based on AAP criteria====
 
====At risk children <12yo child based on AAP criteria====
*Acyclovir 20mg/kg PO q6hrs daily x 5 days
+
*[[Acyclovir]] 20mg/kg PO q6hrs daily x 5 days
*Acyclovir 10mg/kg IV q8hrs daily x 7 days
+
*[[Acyclovir]] 10mg/kg IV q8hrs daily x 7 days
 +
 
 +
====VZIG====
 +
*Initiate VZIG alongside acyclovir for inpatient treatment of child or adult
 +
*For immunocompromised child with exposure, give as post-exposure prophylaxis if<ref>CDC. MMWR - updated recommendations for use of VariZIG - United States, 2013. July 19, 2013 / 62(28);574-576.</ref>:
 +
**Within 10 days window of exposure
 +
**VZIG given IM as 125 IU/10 kg of body weight
 +
***Up to max of 625 IU
 +
***Minimum dose 62.5 IU for patients weighing ≤ 2.0 kg
 +
***Minimum dose 125 IU for weight 2.1 - 10.0 kg
 +
*VZIG may prolong incubation period ≥1 week
 +
**Must have patient closely follow up for signs and symptoms for 28 days after exposure
 +
**If signs or symptoms of varicella occur, antiviral therapy must be started immediately
 +
 
 +
==Disposition==
 +
 
 +
==Vaccine==
 +
*Introduced in 2006. Prior to introduction, incidence prior to adolescence approached 90% in US
 +
*Vaccine is 85% effective against all disease, 90% effective against severe disease (greater than 1000 lesions)
 +
*Typically given at age 5 in USA
 +
*Post-exposure prophylaxis:
 +
**Ideally given within 3-5 days of exposure in immunocompetent patients
 +
**If immunocompromised patient is being given VZIG, varicella vaccine should be administered ≥5 months after VariZIG administration<ref>CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007;56(No. RR-4).</ref>
  
 
==Complications==
 
==Complications==
Line 53: Line 79:
 
[[Pediatric Rashes]]
 
[[Pediatric Rashes]]
  
==Source==
+
==References==
 
<references/>
 
<references/>
  
[[Category:Derm]]
+
[[Category:Dermatology]]
 
[[Category:ID]]
 
[[Category:ID]]
[[Category:Peds]]
+
[[Category:Pediatrics]]

Revision as of 21:03, 10 October 2018

Background

Clinical Features

Male with varicella rash: lesions in various stages of development
Classic blister during early stage of lesion development
  • Pruritic generalized vesicular exanthem with mild systemic manifestations
  • Usually affects children <10y

Rash

  • Starts on trunk or scalp as pruritic, red macules, spreads to extremities
  • Within 24hr rash becomes vesicular (on erythematous base)
  • Palms/soles spared
  • Lesions in various stages of development

Differential Diagnosis

Pediatric Rash

Vesiculobullous rashes

Febrile

Afebrile

Varicella zoster virus

Evaluation

  • Typically made on clinical features

Management

Supportive Care

Antivirals

  • Routine use of antiretrovirals for uncomplicated cases in immunocompetent children is not recommended [1]
  • However, evidence shows decreased days of fever and number of lesions[2]

AAP recommends antiviral treatment (within 24hrs) for patients at risk of increased illness severity:

  • Any patient older than 12 years of age
  • Patients with chronic cutaneous or pulmonary disorders
  • Patients receiving long-term salicylate therapy
  • Patients receiving short, intermittent, or aerosolized courses of corticosteroids

Other cases to consider acyclovir

  • Also consider in [3]:
  • Pregnancy[4]

Immunocompetent Adult

Immunocompromised Adult

At risk children <12yo child based on AAP criteria

VZIG

  • Initiate VZIG alongside acyclovir for inpatient treatment of child or adult
  • For immunocompromised child with exposure, give as post-exposure prophylaxis if[5]:
    • Within 10 days window of exposure
    • VZIG given IM as 125 IU/10 kg of body weight
      • Up to max of 625 IU
      • Minimum dose 62.5 IU for patients weighing ≤ 2.0 kg
      • Minimum dose 125 IU for weight 2.1 - 10.0 kg
  • VZIG may prolong incubation period ≥1 week
    • Must have patient closely follow up for signs and symptoms for 28 days after exposure
    • If signs or symptoms of varicella occur, antiviral therapy must be started immediately

Disposition

Vaccine

  • Introduced in 2006. Prior to introduction, incidence prior to adolescence approached 90% in US
  • Vaccine is 85% effective against all disease, 90% effective against severe disease (greater than 1000 lesions)
  • Typically given at age 5 in USA
  • Post-exposure prophylaxis:
    • Ideally given within 3-5 days of exposure in immunocompetent patients
    • If immunocompromised patient is being given VZIG, varicella vaccine should be administered ≥5 months after VariZIG administration[6]

Complications

  • Can include encephalitis, otitis media, pneumonia, hepatitis, strep/staph superinfection of ruptured vesicles
  • Perinatal infection in neonates may develop serious illness

See Also

Pediatric Rashes

References

  1. Arvin AM: Antiviral therapy for varicella and herpes zoster. Semin Pediatr Infect Dis 2002; 13:12.
  2. Klassen TP, et al. Acyclovir for treating varicella in otherwise healthy children and adolescents. Cochrane Database Syst Rev. 2005; (4):CD002980.
  3. Drugs for non-HIV viral infections. Treat Guidel Med Lett. 2007; 5(59):59-70.
  4. CDC Chicken pox acyclovir treatment [1]
  5. CDC. MMWR - updated recommendations for use of VariZIG - United States, 2013. July 19, 2013 / 62(28);574-576.
  6. CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007;56(No. RR-4).